尼莫地平与丁咯地尔对高龄患者腹部手术后认知功能障碍影响

目的观察高龄患者腹部手术中使用尼莫地平、丁咯地尔对术后认知功能的影响。方法选择择期行腹部手术高龄患者120例,年龄75～90岁,ASAⅠ～Ⅱ级,随机分为3组,尼莫地平组、丁咯地尔组、对照组,每组各40例。尼莫地平组和丁咯地尔组于麻醉前10min开始分别静脉泵入尼莫地平0.25μg.kg-1.min-1和丁咯地尔6μg.kg-1.min-1,至手术结束停药。记录3组患者在麻醉前(T1)、麻醉诱导后(T2)、术中(T3)和手术结束(T4)时的MAP,HR,SPO2,并记录患者术前1d(D1)、术后1d(D2)、术后3d(D3)和术后5d(D4)简易精神状态量表(MMES)评分。结果3组各时点MAP HR SPO2,并无显著差异(P0.05)。D2尼莫地平组,丁咯地尔组各项评分均显著高于对照组(P0.05),且尼莫地平组各项评分显著高于丁咯地尔(P0.05)。D3和D4),尼莫地平组和丁咯地尔组记忆力、执行力评分仍显著高于对照组(P0.05),并且尼莫地平组记忆力,执行力仍高于丁咯地尔组(P0.05)。结论术中使用尼莫地平,丁咯地尔可以改善高龄患者腹部手术术后认知功能,并且尼莫地平更优。     

高良姜素对肺癌肿瘤细胞DNA 拓扑异构酶的抑制及细胞杀伤作用

目的：探讨高良姜素对肺癌肿瘤细胞DNA拓扑异构酶(Topo I)的活性的影响及对肺癌肿瘤细胞株A549和 H46生长的抑制作用。方法：采用MTT 法研究高良姜素对肺癌肿瘤细胞株A549和H46生长的抑制作用,利用琼脂糖凝 胶电泳法测定高良姜素对Topo I活性的影响,在此基础上通过荧光光谱和分子对接研究高良姜素与Topo I的相互作用 机制,最后进一步探讨高良姜素对Topo I结构的影响。结果：高良姜素对肺癌肿瘤细胞株A549和H46的生长起抑制作 用 (半抑制率IC50分别为0.221 mmol/L和0.173 mmol/L);琼脂糖凝胶电泳显示高良姜素对Topo I的活性有较好的抑制作 用;荧光光谱分析显示高良姜素能显著猝灭Topo I的荧光,且疏水作用力是二者相互作用的主要驱动力;圆二色谱分 析表明高良姜素诱导Topo I构象的解折叠,使α-螺旋含量增加,而不利于其形成活性中心,进而导致Topo I活性的降 低;分子模拟结果表明：高良姜素能够优先结合到Topo I的活性中心附近,并与催化基团Arg364和Asn352形成氢键。 结论：高良姜素能够抑制Topo I的活性,而使肿瘤细胞DNA单链解旋的速率降低,从而在诱导肺癌肿瘤细胞株A549和 H46凋亡的过程中起重要作用。     

红景天胶囊抗高原肺水肿的研究进展

红景天胶囊有抗缺血,抗缺氧,抗辐射,抗疲劳,抗病毒等作用,能提高机体免疫机能,有效改善疲劳、脑部缺氧、高原反应等症状。本文对红景天对高原肺水肿的影响机制进行了综述。     

ICL V4c矫正超高度近视术后视觉质量的短期观察

目的：短期观察超高度近视患者植入 ICL V4c术后的视觉质量。

方法：收集植入ICL V4c的超高度近视患者78例100眼的临床资料,术前近视屈光度数为-11.25～-20.00(-13.25±2.05)D,术前裸眼视力<0.10,术前和术后1mo对患者进行视力及屈光状态、对比敏感度及波前像差检查。

结果：术后裸眼视力≥0.7者97眼(97%),≥1.0者37眼(37%)。裸眼视力≥术前矫正视力者90眼(90%)。术后1mo各空间频率的对比敏感度和眩光对比敏感度均明显提高,差异均有统计学意义(均为P<0.05)。术后1mo患者总的高阶像差、彗差、球差、二次彗差及二次球差与术前相比,差异有统计学意义(P<0.05)。术后出现2眼自身晶状体混浊; 2眼眼压增高; 3眼出现角膜反应; 1眼出现夜间眩光和光晕,术后6mo上述症状基本稳定或消失。

结论：短期内超高度近视患者植入ICL V4c术后视觉质量得到了明显提高。     

复方丹参滴丸对应急作训战士血液流变学及血浆去甲肾上腺素影响的研究

目的：探讨复方丹参滴丸对应急作训战士血液流变学及血浆去甲肾上腺素(NE)调理的作用。方法：选新入伍战士80人，随机分为正常组、应急对照组、复方丹参滴丸组、谷维素组，每组20人，口服药物5d后应急作训，观察应急作训后血浆NE、血液流变学的变化。结果：复方丹参滴丸组应急作训后战士血浆NE含量较其他组低．可调整全血黏度。结论：复方丹参滴丸可不同程度地对抗应急作训所致的血浆去甲肾上腺素升高，改善血液流变性。     

硝普钠对高血压病患者动脉功能和血浆血管紧张素Ⅱ浓度的影响

目的　探讨硝普钠对高血压病患者肱动脉功能及血浆血管紧张素Ⅱ (ANGⅡ )含量的影响。方法　用脉冲多普勒检测肱动脉的功能 ;放射免疫法测定血浆ANGⅡ的含量。结果　硝普钠治疗后高血压病患者的血压显著下降 ,心率未见明显变化 ;接受硝普钠治疗后患者的肱动脉管径、血流速度、血流量和扩张性增加 ,血流阻力减少 (P <0 .0 5 ) ;血浆ANGⅡ的测定显示 ,硝普钠治疗后患者血浆ANGⅡ的含量明显降低 (P <0 .0 5 )。结论　硝普钠可明显改善高血压患者肱动脉的顺应性 ,其机制除涉及NO的生成外 ,可能还与血浆ANGⅡ的减少有关。     

三维超声检查在评估CEA后再狭窄中的作用

目的 探讨三维超声在评估颈动脉内膜斑块切除术（CEA）后再狭窄中的价值。方法 回顾性分析2016年3月至2020年2月CEA治疗的272例颈动脉狭窄的临床资料。采用三维超声定量检测术前颈动脉斑块灰阶中位数值（GSM）、总体积（TPV）、GSM/TPV和最大横截面积,以及手术前后残余管腔面积。术后随访6~53个月,中位时间28.5个月,超声或CTA显示残余管腔面积小于术后50%定义为术后再狭窄。结果 272例中,术后发生再狭窄25例[再狭窄组;9.19%（25/272）];再狭窄程度55~89%,平均（74.6±10.3）%。247例未发生再狭窄（未狭窄组）。与未狭窄组相比,再狭窄组术前GSM明显降低（P<0.05）,术后残余管腔面积明显缩小（P<0.05）。两组术前TPV、GSM/TPV、最大横截面积和术前残余管腔面积无统计学差异（P>0.05）。ROC曲线分析结果显示,术前GSM和术后残余管腔面积判断术后再狭窄的曲线下面积分别为0.854（95%置信区间0.798~0.967;P<0.05）、0.866（95%置信区间0.802~0.946;P<0.05）,最佳临界值分别为36.8、139.7 mm2。术前GSM≤36.8预测术后再狭窄的敏感性和特异性分别为84.3%和76.8%。术后残余管腔面积≤139.7 mm2预测再狭窄的敏感性和特异性分别为86.9%和80.5%。结论 CEA治疗单发粥样斑块导致的颈动脉狭窄仍有一定的再狭窄率;三维超声检测颈动脉斑块的多个参数对评估术后再狭窄有较好的应用价值,尤其是GSM和术后残余管腔面积。     

动态血糖监测系统和扫描式血糖监测系统判断2型糖尿病患者黎明现象的一致性研究

目的探讨基于动态血糖监测系统(CGMS)评价扫描式血糖监测系统判断2型糖尿病(T2DM)患者黎明现象的有效性。方法采用便利抽样法,选取2019年6月-2020年6月于新乡市中心医院内分泌科住院的45例T2DM患者为研究对象。患者入院后先佩戴扫描式动态血糖监测系统,48 h后再佩戴CGMS行连续血糖监测,再过72 h后同时取下扫描式动态血糖监测系统和CGMS,核对同时间段的血糖分析报告,判断是否发生黎明现象。采用Kappa检验分析CGMS与扫描式血糖监测系统判断黎明现象的一致性,以CGMS判断结果为标准,绘制扫描式血糖监测系统判断黎明现象的ROC曲线,评定夜间血糖预测黎明现象及次日空腹血糖评估黎明现象的最佳切点值。结果 CGMS判断55.56%(25/45)的患者、扫描式血糖监测系统判断46.67%(21/45)的患者发生黎明现象,两者比较差异无统计学意义(χ2=0.711,P>0.05)。CGMS和扫描式血糖监测系统判断黎明现象的一致性良好(Kappa=0.895,95%CI为1.130~4.883,P<0.01)。夜间血糖预测黎明现象的最佳切点值为8.31 mmol/L,次日空腹血糖评估黎明现象的最佳切点值为7.25 mmol/L,两者的ROC曲线下面积分别为0.729、0.803。结论扫描式血糖监测系统可以准确地判断黎明现象,当夜间血糖值为8.31 mmol/L时提示可能会发生黎明现象,次日空腹血糖值为7.25 mmol/L时提示可能发生了黎明现象。     

Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival

Introduction: miR-32 has recently been found to be implicated in many critical processes in various types of human cancer. However, its clinical significance in human non-small cell lung cancer (NSCLC) has not yet been elucidated. In the present study, we investigated the expression of miR-32 in NSCLC and analyzed its association with clinical features and prognosis of NSCLC patients. Methods: Quantitative real-time PCR (qRT-PCR) was used to measure expression level of miR-32 in lung cancer cell lines, normal bronchial epithelial cells, 90 pairs of tumor samples and adjacent non-tumor tissues. To determine its prognostic value, overall survival was evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis. Results: The expression of miR-32 was significantly decreased in lung cancer cell lines and NSCLC tissues compared with normal bronchial epithelial cells and adjacent non-tumor tissues (P < 0.05). This reduction of miR-32 was associated with tumor stage and lymph node metastasis (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with low miR-32 expression had shorter overall survival time than those with high miR-32 expression (P < 0.05). Univariate analysis revealed statistically significant correlations between overall survival and miR-32 level, tumor stage and lymph node metastasis (P < 0.05). Furthermore, miR-32 levels, tumor stage and lymph node metastasis were independently associated with overall survival (P < 0.05). Conclusions: Our results provided the first evidence that down-regulation of miR-32 was correlated with NSCLC progression, and miR-32 might be a potential molecular biomarker for predicting the prognosis of patients.     

Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma

Introduction: Long non-coding RNA MEG3 (lncRNA MEG3) has been showed to involve in a variety of cancers. However, the association between lncRNA MEG3 expression level and the prognosis of osteosarcoma is still unclear. Methods: The expression levels of lncRNA MEG3 in osteosarcoma tissues and adjacent non-tumor tissues were detected using quantitative real-time PCR (qRT-PCR). Differences in patient survival were determined using the Kaplan-Meier method and a log-rank test. A Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. Results: Our findings showed that expression of lncRNA MEG3 was clearly lower in osteosarcoma tissues compared with adjacent non-tumor tissues. The expression of lncRNA MEG3 was associated with clinical stage and distant metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low lncRNA MEG3 expression had a shorter overall survival (log-rank test, P<0.05). Furthermore, multivariate analysis revealed that decreased expression of lncRNA MEG3, advanced clinical stage and distant metastasis were all independent predictors to overall survival of osteosarcoma patients. Conclusions: Downregulation of lncRNA MEG3 was associated with poor overall survival of osteosarcoma. LncRNA MEG3 could be a useful biomarker for progression and prognosis of osteosarcoma.